Anti-MEK1 (phospho S298) antibody (ab5613)
Key features and details
- Rabbit polyclonal to MEK1 (phospho S298)
- Suitable for: WB
- Reacts with: Mouse
- Isotype: IgG
Overview
-
Product name
Anti-MEK1 (phospho S298) antibody
See all MEK1 primary antibodies -
Description
Rabbit polyclonal to MEK1 (phospho S298) -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species WB Mouse
-
Immunogen
The antiserum was produced against a chemically synthesized phosphopeptide derived from a region of human MEK 1 that contains serine 298.
-
Positive control
- NIH3T3 cells +/- PDGF, A431 +/- EGF, PC12 +/- NGF.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
pH: 7.3
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.1% BSA
BSA is IgG and protease free -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated MEK 1. The final product is generated by affinity chromatography using a MEK 1 derived peptide that is phosphorylated at serine 298. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab5613 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
| Application | Species |
|---|---|
| WB |
Mouse
|
| Application | Abreviews | Notes |
|---|---|---|
| WB |
Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 50 kDa.
|
| Notes |
|---|
|
WB
Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 50 kDa. |
Target
-
Function
Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases. -
Tissue specificity
Widely expressed, with extremely low levels in brain. -
Involvement in disease
Defects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant. -
Sequence similarities
Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway. - Information by UniProt
-
Database links
- Entrez Gene: 26395 Mouse
- SwissProt: P31938 Mouse
- Unigene: 248907 Mouse
-
Alternative names
- Dual specificity mitogen activated protein kinase kinase 1 antibody
- Dual specificity mitogen-activated protein kinase kinase 1 antibody
- ERK activator kinase 1 antibody
see all
Images
-
Western blot - Anti-MEK1 (phospho S298) antibody (ab5613)
Peptide Competition: Extracts prepared from NIH3T3 cells treated with PDGF were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4oC, then were incubated with 0.50
µ g/mL ab5613 antibody for two hours at room temperature, following prior incubation with: the phosphopeptide immunogen (1), the nonphosphopeptide corresponding to the immunogen (2), a generic phosphoserine containing peptide (3), or, no peptide (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method.Phosphatase Stripping: Extracts prepared from NIH3T3 cells not treated or treated (+PDGF) with PDGF were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. The membrane was either treated (lane 5) or not treated (lanes 6, 7) with lambda phosphatase, then incubated with 0.50
µ g/mL ab5613 antibody for two hours at room temperature. After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to ab5613 blocks the antibody signal, demonstrating the specificity of the antibody. The data also show that phosphatase stripping eliminates the signal, verifying that the antibody is phospho-specific.
Peptide Competition: Extracts prepared from NIH3T3 cells treated with PDGF were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4oC, then were incubated with 0.50 µg/mL ab5613 antibody for two hours at room temperature, following prior incubation with: the phosphopeptide immunogen (1), the nonphosphopeptide corresponding to the immunogen (2), a generic phosphoserine containing peptide (3), or, no peptide (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. Phosphatase Stripping: Extracts prepared from NIH3T3 cells not treated or treated (+PDGF) with PDGF were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. The membrane was either treated (lane 5) or not treated (lanes 6, 7) with lambda phosphatase, then incubated with 0.50 µg/mL ab5613 antibody for two hours at room temperature. After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to ab5613 blocks the antibody signal, demonstrating the specificity of the antibody. The data also show that phosphatase stripping eliminates the signal, verifying that the antibody is phospho-specific.
Datasheets and documents
References (2)
ab5613 has been referenced in 2 publications.
- Zhu AD et al. lncRNA-ATB promotes viability, migration, and angiogenesis in human microvascular endothelial cells by sponging microRNA-195. J Cell Biochem N/A:N/A (2019). PubMed: 30983015
- Tanaka A et al. Toll-like receptor 4 agonistic antibody promotes innate immunity against severe pneumonia induced by coinfection with influenza virus and Streptococcus pneumoniae. Clin Vaccine Immunol 20:977-85 (2013). PubMed: 23637040
